Branaplam on FDA’s Fast Track; Phase 2 Trial Now Enrolling

Branaplam on FDA’s Fast Track; Phase 2 Trial Now Enrolling

315039

Branaplam on FDA’s Fast Track; Phase 2 Trial Now Enrolling

The experimental oral medication branaplam (LMI070) has been granted fast track designation by the U.S. Food and Drug Administration (FDA) as a potential treatment for Huntington’s disease, according to an announcement from the therapy’s developer, Novartis. This designation is designed to speed the development and review of investigational medicines that have the potential to substantially improve care for serious diseases and fill unmet medical needs. Branaplam received orphan drug designation from the FDA in 2020.…

You must be logged in to read/download the full post.